Percutaneous delivery of liquid tetracycline using a thermal resurfacing drug delivery system for the treatment of festoons

IF 2.2 3区医学 Q2 DERMATOLOGY

Lasers in Surgery and Medicine Pub Date : 2024-04-11 DOI:10.1002/lsm.23786

Margarita Safir MD, Inbar Waizer MD, Ari Safir MD, Morris E. Hartstein MD, Ofir Artzi MD

{"title":"Percutaneous delivery of liquid tetracycline using a thermal resurfacing drug delivery system for the treatment of festoons","authors":"Margarita Safir MD, Inbar Waizer MD, Ari Safir MD, Morris E. Hartstein MD, Ofir Artzi MD","doi":"10.1002/lsm.23786","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objectives</h3>\n \n <p>To examine the effects of percutaneous tetracycline delivery to the malar area using a thermomechanical device (Tixel) in patients suffering from festoons.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This retrospective study included patients who underwent combination treatment with a thermomechanical device (Tixel) followed by application of topical tetracycline 1% at two private clinics between 2019 and 2023. Demographic and medical data, treatment parameters along with before and after treatment photographs were retrieved retrospectively. All patients were asked to answer a questionnaire, assessing self-reported pre and posttreatment disturbance, patient global impression of change (PGIC) score, overall satisfaction with treatment, and the onset and duration of treatment effect. Finally, three masked reviewers evaluated and graded the severity of before and after treatment photographs.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Twenty healthy patients received the combination treatment. The mean age was 59.4 ± 8.2 years (range: 45–72 years), and 90.0% (<i>n</i> = 18) were female. The number of treatment sessions per patient ranged from 2 to 8, mean of 5.0 ± 1.9, performed at 5.4 ± 1.2-week intervals. The masked reviewers' grading scores demonstrated a significant improvement (2.81 ± 1.3 before vs. 1.6 ± 1.1 after, <i>p</i> < 0.001). The self-reported disturbance caused by the festoons improved significantly as well (4.7 ± 0.98 vs. 1.7 ± 1.1, <i>p</i> < 0.001). On the PGIC score, 85% (17/20) reported moderate (grade 5) to significant (grade 7) improvement of symptoms and life quality after treatment. Improvement onset was reported to occur 11.2 ± 6.6 days after the first treatment (range 2−30 days), and 90% (18/20) of the patients reported improvement lasting at least 4 months after completion of the second treatment.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Topical tetracycline application following Tixel treatment induced significant improvement in patient with festoons.</p>\n </section>\n </div>","PeriodicalId":17961,"journal":{"name":"Lasers in Surgery and Medicine","volume":"56 5","pages":"454-461"},"PeriodicalIF":2.2000,"publicationDate":"2024-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Lasers in Surgery and Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/lsm.23786","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

To examine the effects of percutaneous tetracycline delivery to the malar area using a thermomechanical device (Tixel) in patients suffering from festoons.

Methods

This retrospective study included patients who underwent combination treatment with a thermomechanical device (Tixel) followed by application of topical tetracycline 1% at two private clinics between 2019 and 2023. Demographic and medical data, treatment parameters along with before and after treatment photographs were retrieved retrospectively. All patients were asked to answer a questionnaire, assessing self-reported pre and posttreatment disturbance, patient global impression of change (PGIC) score, overall satisfaction with treatment, and the onset and duration of treatment effect. Finally, three masked reviewers evaluated and graded the severity of before and after treatment photographs.

Results

Twenty healthy patients received the combination treatment. The mean age was 59.4 ± 8.2 years (range: 45–72 years), and 90.0% (n = 18) were female. The number of treatment sessions per patient ranged from 2 to 8, mean of 5.0 ± 1.9, performed at 5.4 ± 1.2-week intervals. The masked reviewers' grading scores demonstrated a significant improvement (2.81 ± 1.3 before vs. 1.6 ± 1.1 after, p < 0.001). The self-reported disturbance caused by the festoons improved significantly as well (4.7 ± 0.98 vs. 1.7 ± 1.1, p < 0.001). On the PGIC score, 85% (17/20) reported moderate (grade 5) to significant (grade 7) improvement of symptoms and life quality after treatment. Improvement onset was reported to occur 11.2 ± 6.6 days after the first treatment (range 2−30 days), and 90% (18/20) of the patients reported improvement lasting at least 4 months after completion of the second treatment.

Conclusions

Topical tetracycline application following Tixel treatment induced significant improvement in patient with festoons.

查看原文本刊更多论文

利用热重塑给药系统经皮给药液态四环素以治疗静脉曲张

方法这项回顾性研究纳入了2019年至2023年期间在两家私人诊所接受热机械装置（Tixel）联合治疗，然后外敷1%四环素的患者。研究人员回顾性地检索了患者的人口统计学数据、医疗数据、治疗参数以及治疗前后的照片。所有患者都被要求回答一份问卷，评估自我报告的治疗前和治疗后干扰、患者总体变化印象（PGIC）评分、对治疗的总体满意度以及治疗效果的开始和持续时间。最后，三名蒙面评审员对治疗前后照片的严重程度进行了评估和分级。平均年龄为 59.4 ± 8.2 岁（范围：45-72 岁），90.0%（n = 18）为女性。每位患者的治疗次数为 2 至 8 次不等，平均为 5.0 ± 1.9 次，治疗间隔为 5.4 ± 1.2 周。蒙面评审员的评分结果显示，患者的病情有了明显改善（治疗前为 2.81 ± 1.3，治疗后为 1.6 ± 1.1，p <0.001）。患者自我报告的褶皱造成的干扰也有明显改善（4.7 ± 0.98 vs. 1.7 ± 1.1，p < 0.001）。在 PGIC 评分中，85%（17/20）的患者表示治疗后症状和生活质量得到了中度（5 级）到明显（7 级）的改善。据报告，第一次治疗后 11.2 ± 6.6 天（2-30 天不等）病情开始好转，90%（18/20）的患者报告在第二次治疗后病情好转持续了至少 4 个月。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Lasers in Surgery and Medicine 医学-外科

CiteScore

5.40

自引率

12.50%

发文量

119

审稿时长

1 months

期刊介绍： Lasers in Surgery and Medicine publishes the highest quality research and clinical manuscripts in areas relating to the use of lasers in medicine and biology. The journal publishes basic and clinical studies on the therapeutic and diagnostic use of lasers in all the surgical and medical specialties. Contributions regarding clinical trials, new therapeutic techniques or instrumentation, laser biophysics and bioengineering, photobiology and photochemistry, outcomes research, cost-effectiveness, and other aspects of biomedicine are welcome. Using a process of rigorous yet rapid review of submitted manuscripts, findings of high scientific and medical interest are published with a minimum delay.